Gyre Therapeutics (GYRE) Operating Expenses (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Operating Expenses of $31.9 million for Q1 2026, up 61.1% year-over-year from $19.8 million in Q1 2025, and down 21.78% quarter-over-quarter from $40.8 million in Q4 2025.
Gyre Therapeutics (GYRE) Operating Expenses (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Operating Expenses for 17 consecutive years, with $31.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 61.1% year-over-year to $31.9 million; the TTM figure through Mar 2026 stood at $119.7 million (up 35.19% YoY), while the FY2025 annual figure was $105.1 million, up 17.31% from the prior year.
- Operating Expenses slipped to $31.9 million in Q1 2026 per GYRE's latest filing, from $40.8 million in the prior quarter.
- Across five years, Operating Expenses topped out at $124.0 million in Q4 2022 and bottomed at -$51.5 million in Q2 2022.
- Historically, Operating Expenses has averaged $29.5 million across 5 years, with a median of $21.3 million in 2024.
- On a YoY basis, Operating Expenses climbed as much as 444.79% in 2022 and fell as far as 344.84% in 2022.
- Gyre Therapeutics' Operating Expenses stood at $124.0 million in 2022, then slipped by 4.18% to $118.8 million in 2023, then sank by 77.09% to $27.2 million in 2024, then surged by 49.78% to $40.8 million in 2025, then dropped by 21.78% to $31.9 million in 2026.
- Business Quant data shows GYRE's Operating Expenses at $31.9 million in Q1 2026, $40.8 million in Q4 2025, and $23.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 43.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.47 Mn |
| Mar 31, 2026 | 31.87 Mn |
| Dec 31, 2025 | 40.75 Mn |
| Sep 30, 2025 | 23.64 Mn |
| Jun 30, 2025 | 23.45 Mn |
| Mar 31, 2025 | 19.79 Mn |
| Dec 31, 2024 | 27.21 Mn |
| Sep 30, 2024 | 20.30 Mn |
| Jun 30, 2024 | 21.26 Mn |
| Mar 31, 2024 | 19.10 Mn |
| Dec 31, 2023 | 118.78 Mn |
| Sep 30, 2023 | 19.28 Mn |
| Jun 30, 2023 | 24.36 Mn |
| Mar 31, 2023 | 18.27 Mn |
| Dec 31, 2022 | 123.96 Mn |
| Sep 30, 2022 | 5.17 Mn |
| Jun 30, 2022 | -51.53 Mn |
| Mar 31, 2022 | 15.50 Mn |
| Dec 31, 2021 | 22.75 Mn |
| Sep 30, 2021 | 27.53 Mn |